Open AccessBiosimilar Rituximab (Redditux) Added to CHOP Chemotherapy for De Novo Diffuse Large B-Cell Lymphoma Patients: Real-Life Single-Center Experience
Author(s) -
Murat Özbalak,
Metban Mastanzade,
Özden Özlük,
Tarık Onur Tiryaki,
Simge Erdem,
Ezgi Pınar Özbalak,
Tuğrul Elverdi,
İpek Yönal Hindilerden,
Ali Altay,
Gülçin Yeğen,
Ahmet Emre Eşkazan,
Muhlis Cem Ar,
Mustafa Nuri Yenerel,
Teoman Soysal,
Meliha Nalçacı,
Burhan Ferhanoğlu,
Sevgi Kalayoğlu Beşışık
Publication year - 2022
Publication title -
turkish journal of hematology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.351
H-Index - 16
ISSN - 1300-7777
DOI - 10.4274/tjh.galenos.2022.2022.0142
Subject(s) - medicine , rituximab , chop , regimen , biosimilar , cohort , gastroenterology , single center , confidence interval , lymphoma , international prognostic index , surgery
Redditux ® (RED), as a biosimilar rituximab, was approved in Turkey for all indications of the original Mabthera ® (MAB) in March 2018. The aim of our study was to evaluate the efficacy and safety of RED in de novo diffuse large B-cell lymphoma.